Your browser doesn't support javascript.
loading
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma.
Ye, Dingwei; Liu, Jiyan; Zhou, Aiping; Zou, Qing; Li, Hanzhong; Fu, Cheng; Hu, Hailong; Huang, Jian; Zhu, Shaoxing; Jin, Jie; Ma, Lulin; Guo, Jianming; Xiao, Jun; Park, Se Hoon; Zhang, Dahong; Qiu, Xiusong; Bao, Yuanyuan; Zhang, Lilin; Shen, Wei; Bi, Feng.
Afiliação
  • Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Liu J; Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhou A; Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Institute & Hospital, Beijing, China.
  • Zou Q; Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, China.
  • Li H; Department of Urology, Peking Union Medical College Hospital, Beijing, China.
  • Fu C; Department of Urological Surgical Oncology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
  • Hu H; Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Huang J; Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Zhu S; Department of Medical Oncology, Zhejiang Cancer Hospital, Zhejiang, China.
  • Jin J; Department of Urology, Peking University First Hospital, Beijing, China.
  • Ma L; Department of Urology, Peking University Third Hospital, Beijing, China.
  • Guo J; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Xiao J; Department of Urology, Anhui Provincial Hospital, Hefei, China.
  • Park SH; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
  • Zhang D; Department of Urology, Zhejiang Provincial People's Hospital, Zhejiang, China.
  • Qiu X; Department of Medical Oncology, BeiGene (Beijing) Co., Ltd, Beijing, China.
  • Bao Y; Department of Medical Oncology, BeiGene (Beijing) Co., Ltd, Beijing, China.
  • Zhang L; Department of Medical Oncology, BeiGene (Beijing) Co., Ltd, Beijing, China.
  • Shen W; Department of Medical Oncology, BeiGene (Beijing) Co., Ltd, Beijing, China.
  • Bi F; Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China.
Cancer Sci ; 112(1): 305-313, 2021 Jan.
Article em En | MEDLINE | ID: mdl-33047430
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células de Transição / Neoplasias Urológicas / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células de Transição / Neoplasias Urológicas / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article